Journal Of Clinical Oncology (jco) Podcast
Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Patients
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:06
- Mas informaciones
Informações:
Sinopsis
By Reed Drews. This JCO Podcast provides observations and commentary on the JCO article, "Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh Pardanani, et al.
